Clinical Trials & Research Studies in Canada(Updated 8/25)

North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)

NCT01694940

Recruiting

The North American Mitochondrial Disease Consortium (NAMDC) maintains a patient contact registry and tissue biorepository for patients with mitochondrial disorders.

Gender:

ALL

Ages:

All

Trial Updated:

09/03/2024

Locations: University of California San Diego, San Diego, California +16 locations

Conditions: Mitochondrial Disorders, Mitochondrial Genetic Disorders, Mitochondrial Diseases, Disorder of Mitochondrial Respiratory Chain Complexes, Deletion and Duplication of Mitochondrial DNA

Register for Updates

Learn More ›

The Role of IL-23-Responsive Immune Cell Subsets in Post-Operative Recurrence in Patients With Crohn's Disease.

NCT06006039

Recruiting

Inflammatory Bowel Diseases (IBDs), including ulcerative colitis and Crohn's disease (CD), constitute a group of debilitating chronic diseases that profoundly impact patient quality of life and incurs large costs in terms of treatment and lost productivity. Incidence of IBD is rising worldwide, and there is a pressing clinical need for development of new therapies. Discovery and development of effective therapies to treat IBDs depend first on a better understanding of the underlying mechanisms,... Read More

Inflammatory Bowel Diseases (IBDs), including ulcerative colitis and Crohn's disease (CD), constitute a group of debilitating chronic diseases that profoundly impact patient quality of life and incurs large costs in terms of treatment and lost productivity. Incidence of IBD is rising worldwide, and there is a pressing clinical need for development of new therapies. Discovery and development of effective therapies to treat IBDs depend first on a better understanding of the underlying mechanisms, including how proinflammatory cells proliferate unchecked. It has been established that the cytokine interleukin (IL)-23 plays a pivotal role in IBD pathophysiology and antibodies targeting IL-23 are currently in late stage development for the treatment of both CD and ulcerative colitis (UC). IL-23 is part of the IL-12 family of cytokines (which includes IL-12, IL-27 and IL-35). The p40 subunit is shared among IL-23 and IL-12; the p19 subunit is unique to IL-23. Thus far, the efficacy of selective anti-IL-23 blockade (via anti-p19 antibodies) appears 5-10% better with respect to clinical and endoscopic outcomes than targeting both IL-23 and IL-12 using anti-p40 antibodies. Understanding the effects of IL-23 (and IL-12) in IBDs requires identification of the most relevant immune cells that respond to these cytokines. One likely cell type controlled by the IL-23 pathway are innate lymphoid cells (ILCs). ILC3s (a subset of ILCs) are dominant in healthy intestinal tissue and capable of producing IL-22 which maintain intestinal epithelial homeostasis. Disturbances in the amounts of IL-22 caused by changes in the stimulatory cytokine IL-23 in tissues, may therefore cause inflammatory responses. IL-23 may facilitate the IL-12-induced shift of ILC3s to ILC1s which are contributing to the disease-causing chronic inflammation. The DIVE 23 project is designed to understand the role of IL-23 in human IBD, in particular CD. It is hypothesized that IL-23R+ cells in the gut, are drivers of chronic inflammation in CD and determine the impact of IL-23 inhibition. To this end the investigators plan to extensively characterize the IL-23-responsive cell populations in inflamed and non-inflamed intestinal tissues of CD patients with postoperative recurrence in order to identify IL-23-responsive immune cell populations that are associated with disease activity. Patients will be treated in routine medical practice with biological agents and will undergo a second ileocolonoscopy 12-16 weeks later to investigate the impact of the different interventions on the mucosal immunology driving CD. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

09/02/2024

Locations: Mount Sinai, Toronto, Ontario +1 locations

Conditions: Crohn´s Disease

Register for Updates

Learn More ›

Neuroblastoma Biology Study

NCT01587300

Recruiting

Medical scientists want to find better ways to treat neuroblastoma and to find ways to prevent the tumor from growing back. To do this, they need more information about the characteristics of neuroblastoma cells. Therefore, they want to study samples of neuroblastoma tissues and neuroblastoma and normal cells in the blood and bone marrow that may be related to the growth of neuroblastoma cells. Doctors and other medical scientists also want to find better ways to detect and measure neuroblastoma... Read More

Gender:

ALL

Ages:

Between 31 days and 99 years

Trial Updated:

09/01/2024

Locations: Children's Hospital Los Angeles, Los Angeles, California +16 locations

Conditions: Neuroblastoma

Register for Updates

Learn More ›

Smart About Meds (SAM) RCT

NCT05371548

Recruiting

Introduction: Almost half of patients discharged from hospital are re-admitted or return to the emergency department (ED) within 90 days. Patient nonadherence to medication changes during hospitalization and the use of potentially inappropriate medications (PIMs) both contribute to the risk of adverse events post-discharge. Smart About Meds (SAM) is a patient-centered mobile application designed to target medication nonadherence and PIMs use. This protocol describes a randomized controlled tria... Read More

Introduction: Almost half of patients discharged from hospital are re-admitted or return to the emergency department (ED) within 90 days. Patient nonadherence to medication changes during hospitalization and the use of potentially inappropriate medications (PIMs) both contribute to the risk of adverse events post-discharge. Smart About Meds (SAM) is a patient-centered mobile application designed to target medication nonadherence and PIMs use. This protocol describes a randomized controlled trial (RCT) to evaluate the effectiveness of SAM. Methods \& Analysis: A pragmatic, stratified RCT will be conducted among 3,250 patients discharged from internal medicine, cardiac care, cardiac surgery, vascular surgery, and respiratory units of the Royal Victoria Hospital and the Montreal General Hospital. At discharge, patients will be randomized 1:1 to usual care or the SAM intervention. SAM integrates novel user-centered features (e.g. continuously updated medication list with pill images, side-effect checker, interaction checker) with pharmacist monitoring to tackle post-discharge nonadherence to new medication regimens. SAM also notifies patients of PIMS in their regimen, with advice to discuss with their physician. Following discharge, patients will be followed for 90 days, during which the occurrence of the composite outcome of ED visits, hospital readmissions, or death will be measured. Secondary outcomes will include the individual components of the composite outcome, nonadherence to medication changes, defined as failure to fill a new prescription, filling a modified prescription at the incorrect dose, or filling discontinued medications, secondary medication adherence, patient empowerment, and health-related quality of life. An intention-to-treat analysis will evaluate the effectiveness of SAM. Multivariable logistic regression will estimate differences between treatment groups in the proportion of patients nonadherent to at least one medication change. With a sample size of 3,250, there will be 80% power to detect a 5% absolute reduction in this outcome. Two-way interaction terms will test hypothesized modifiers of SAM's effectiveness, including hospital, unit, age, sex, gender and comorbidity burden. Binary and continuous secondary outcomes will be assessed using multivariable logistic and linear regression, respectively. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/30/2024

Locations: McGill University Health Centre, Montreal, Quebec

Conditions: Medication Adherence

Register for Updates

Learn More ›

Fasting-mimicking Diet in Treatment of Depressive Symptoms in IBD

NCT05382897

Recruiting

Inflammatory bowel disease (IBD) is a chronic illness characterized by inflammation of the intestine. Many individuals with IBD suffer from depressive symptoms and anxiety which can lead to a decreased quality of life, poor treatment compliance, and higher morbidity and mortality. The object of this clinical trial is to investigate the effects of a fasting mimicking diet in IBD patients who are suffering with symptoms of depression. Participants will carry out 3 cycles of a 5-day period of a pla... Read More

Gender:

ALL

Ages:

Between 18 years and 65 years

Trial Updated:

08/30/2024

Locations: University of Alberta Hospital, Edmonton, Alberta +1 locations

Conditions: Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis

Register for Updates

Learn More ›

Real-World Effectiveness of Mavacamten in Canada

NCT06338202

Recruiting

The purpose of this observational, retrospective, physician survey study is to describe the real-world effectiveness and use of mavacamten in participants who initiated treatment for obstructive hypertrophic cardiomyopathy (oHCM) in Canada.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/30/2024

Locations: London Health Science Centre (LHSC), London, Ontario

Conditions: Obstructive Hypertrophic Cardiomyopathy (oHCM)

Register for Updates

Learn More ›

Study Looking at Biomarkers in Ovarian Cancer

NCT03419689

Recruiting

This is a sample study that will collect biological samples (blood, tumor tissue, ascites, and/or other fluids) from gynecological cancer patients for biomarker research. In addition, the results of the testing done on the samples will be given to the participant's treating physician who may use the information to guide treatment decisions.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

08/28/2024

Locations: Royal Victoria Regional Health Centre, Barrie, Ontario +6 locations

Conditions: Gynecologic Cancer

Register for Updates

Learn More ›

Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs

NCT04613921

Recruiting

Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-thre... Read More

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

08/27/2024

Locations: Cedars-Sinai Comprehensive Transplant Center, Los Angeles, California +105 locations

Cedars-Sinai Comprehensive Transplant Center, Los Angeles, California

University of Colorado, Aurora, Colorado

Tampa General Hospital, Tampa, Florida

Piedmont Healthcare, Atlanta, Georgia

Northwestern Memorial Hospital, Chicago, Illinois

The University of Chicago Medicine, Chicago, Illinois

University of Maryland School of Medicine, Baltimore, Maryland

Weill Cornell Medicine, New York, New York

Icahn School of Medicine at Mount Sinai, New York, New York

Montefiore Medical Center, New York, New York

University of Cincinnati, Cincinnati, Ohio

Cleveland Clinic, Cleveland, Ohio

University of Pennsylvania, Philadelphia, Pennsylvania

Vanderbilt University Medical Center, Nashville, Tennessee

Baylor College of Medicine (Scott & White), Dallas, Texas

Michael E DeBakey VA Medical Center, Houston, Texas

Baylor St. Luke's Medical Centre, Houston, Texas

University of Utah Health, Salt Lake City, Utah

Austral University Hospital, Buenos Aires, Not set

Hospital Alemán, Buenos Aires, Not set

Italian Hospital in Buenos Aires, Buenos Aires, Not set

Austin Hospital, Heidelberg, Not set

Sir Charles Gairdner Hospital, Nedlands, Not set

Royal Prince Alfred Hospital, Sydney, Not set

Medical University of Vienna, Department of Transplant Surgery, Wien, Not set

CUB Erasme Hospital, Brussels, Not set

Ghent University Hospital, Ghent, Not set

UZ Leuven, Leuven, Not set

Walter Cantídio University Hospital, Fortaleza, Not set

Irmandade Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Not set

Hospital das Clínicas da Universidade de São Paulo, São Paulo, Not set

University of Alberta, Edmonton, Not set

University of Toronto, Multiorgan Transplant Program, Toronto, Not set

Pablo Tobón Uribe Hospital, Medellín, Not set

Institute for Clinical and Experimental Medicine, Praha, Not set

APHP Beaujon, Clichy, Not set

APHP Henri Mondor, Créteil, Not set

Hôpital de la Croix-Rousse, Lyon, Not set

CHU Montpellier-Hôpital Saint Eloi, Montpellier, Not set

APHP Hôpitaux Universitaires Pitié Salpêtrière, Paris, Not set

CHU Rennes, Hôpital De Pontchaillou, Rennes, Not set

Hautepièrre Hospital, Service de Réanimation Médicale, Strasbourg, Not set

Trousseau Hospital,, Tours, Not set

Hôpital Paul Brousse, Villejuif, Not set

University Hospital Regensburg, Regensburg, Eastern Bavaria

Universitätsklinikum Schleswig-Holstein (UKSH), Kiel, Schleswig-Holstein

University Hospital Aachen, Aachen, Not set

Charité University Hospital, Berlin, Not set

Goethe University Clinic, Frankfurt, Not set

University Medical Center, Hamburg Eppendorf, Hamburg, Not set

Hannover Medical School, Hannover, Not set

University Hospital Heidelberg, Heidelberg, Not set

Jena University Hospital, Jena, Not set

Universitätsklinikum Schleswig-Holstein (UKSH), Kiel, Not set

Leipzig University Hospital, Leipzig, Not set

University Hospital Mainz, Mainz, Not set

LMU Großhadern, Munich, Not set

UKM Muenster, Münster, Not set

University Hospital Tübingen, Tübingen, Not set

Queen Mary Hospital, The University of Hong Kong, Hong Kong, Not set

Indraprastha Apollo Hospitals, New Delhi, Delhi

Aster CMI Hospital, Bengaluru, Karnataka

Kasturba Hospital, Mumbai, Maharashtra

Seth GSMC & KEM Hospital, Mumbai, Maharashtra

Mahatma Gandhi University of Medical Sciences and Technology, Jaipur, Rajasthan

Dr.Rela Institute & Medical Centre, Chennai, Not set

Fortis Hospital Noida, FEHI, FMRI, Gurugramam, Not set

Medanta Medicity, Gurugramam, Not set

Amrita Institute of Medical Sciences, Kochi, Not set

Global Hospital. Super speciality & transplant centre, Mumbai, Not set

Max Saket Hospital, New Delhi, Not set

Yashoda Hospitals, Secunderabad, Not set

Ospedale Papa Giovanni XXIII-, Bergamo, Not set

S.Orsola Hospital - Alma Mater Studiorum University of Bologna, Bologna, Not set

Ca' Granda. Policlinico Milano, Milan, Not set

Niguarda Hospital, Milan, Not set

University and Hospital of Padova, Padova, Not set

Kyushu University Hospital, Fukuoka, Not set

Hiroshima University Hospital, Hiroshima, Not set

Kyoto University Hospital, Kyoto, Not set

Nagasaki University Hospital, Nagasaki, Not set

Tokyo University Hospital, Tokyo, Not set

Samsung Medical Center, Seoul, Not set

Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Not set

University Medical Center Groningen (UMCG), Groningen, Not set

Erasmus MC University Medical Center, Rotterdam, Not set

Auckland City Hospital- New Zealand Liver Transplant Unit, Auckland, Not set

Medical University of Warsaw, Dept. of General, Transplant & Liver Surgery, Warsaw, Not set

Hospital Curry Cabral, Lisboa, Not set

Hospital Clinic in Barcelona, Barcelona, Not set

Hospital Vall d'Hebron, Barcelona, Not set

Hospital Universitario 12 de Octubre, Madrid, Not set

Hospital Universitario Ramón y Cajal, Madrid, Not set

Hospital Marqués de Valdecilla, Santander, Not set

Hospital Universitario Virgen del Rocío, Sevilla, Not set

Hospital Universitari i Politècnic La Fe, Valencia, Not set

Karolinska Institutet, Stockholm, Not set

Geneva University Hospital (HUG), Geneva, Not set

Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Not set

Inonu University, Liver Transplantation Institute, Malatya, Anatolia

Istanbul Memorial Bahcelievler Hospital, Istanbul, Not set

Queen Elizabeth Hospital Birmingham, Birmingham, Not set

Scottish Liver Transplant Unit, Royal Infirmary, Edinburgh, Not set

Leeds Teaching Hospitals NHS Trust, Leeds, Not set

King's College Hospital, London, Not set

Royal Free Hospital, London, Not set

Conditions: Liver Diseases, Liver Cirrhosis, Acute-On-Chronic Liver Failure, Liver Transplant; Complications

Register for Updates

Learn More ›

Functional Evolution of Traumatic Brain Injured Adults During Rehabilitation and Social Participation

NCT05022940

Recruiting

The research project aims to better understand the multiple factors related to the clinical evolution and the social participation of traumatic brain injured (TBI). The project will provide better understanding of the patients' evolution during rehabilitation after TBI in terms of adaptation and social participation, assess the effect of rehabilitation and study social participation outcomes and quality of life of TBI patients one-year post-rehabilitation. Project benefits include improvement of... Read More

Gender:

ALL

Ages:

17 years and above

Trial Updated:

08/27/2024

Locations: CRIR, Montreal, Quebec

Conditions: Traumatic Brain Injury

Register for Updates

Learn More ›

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

NCT05870748

Recruiting

A Phase 2/3 study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

08/27/2024

Locations: Arizona Oncology Associates, PC-Hope, Tucson, Arizona +38 locations

Arizona Oncology Associates, PC-Hope, Tucson, Arizona

Sutter Health, Daly City, California

MedStar Washington Hospital Center, Washington, District of Columbia

Baptist Health South Florida (BHSF) - Miami Cancer Institute, Miami, Florida

USF Research & Innovation, Tampa, Florida

Sinai Hospital of Baltimore, Baltimore, Maryland

University of Massachusetts Chan Medical School, Worcester, Massachusetts

Minnesota Oncology Hematology, Minneapolis, Minnesota

Nebraska Methodist Hospital, Omaha, Nebraska

Optimum Clinical Research Group, Albuquerque, New Mexico

NYU Langone Health, New York, New York

Good Samaritan Hospital Medical Center, West Islip, New York

University of Cincinnati Medical Center, Cincinnati, Ohio

Ohio State University Center, Columbus, Ohio

Kettering Health, Kettering, Ohio

Oklahoma Cancer Specialists and Research Institute- Tulsa Cancer Center, Tulsa, Oklahoma

Oncology Associates of Oregon, PC, Eugene, Oregon

Providence Gynecologic Oncology Clinic, Portland, Oregon

Lancaster General Hospital, Lancaster, Pennsylvania

Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, Philadelphia, Pennsylvania

Texas Oncology, Dallas, Texas

Texas Oncology-DFW, Dallas, Texas

Texas Oncology-San Antonio, San Antonio, Texas

Texas Oncology - The Woodlands, The Woodlands, Texas

Virginia Cancer Specialists, Fairfax, Virginia

Chris O'Brien Lifehouse, Camperdown, New South Wales

Prince of Wales Hospital, Randwick, New South Wales

Westmead Hospital, Westmead, New South Wales

McGill University Health Centere (MUHC)-Glen Site, Montréal, Quebec

Princess Margaret Cancer Center, Toronto, Not set

Sheba Medical Center, Ramat Gan, Not set

Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do

Keimyung University Dongsan Hospital, Daegu, Not set

National Cancer Center, Gyeonggi-do, Not set

Gachon University Gil Hospital, Incheon, Not set

Yonsei University, Severance Hospital, Seoul, Not set

Health New Zealand - Te Whatu Ora Capital, Coast, and Hutt Valley - Wellington Regional Hospital, Newtown, Wellington

Curie Centre, Oncology centre, Novena, Not set

National Cancer Center Singapore, Singapore, Not set

Conditions: Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer

Register for Updates

Learn More ›

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

NCT06485076

Recruiting

Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in goals of care conversations occurring late in the illness trajectory and aggressive care being received in the last 30 days of life. Early palliative care alongside usual cancer care has been shown to improve patient outcomes such as symptom burden, mood, and quality of lif... Read More

Patients with multiple myeloma experience a wide range of physical and psychological symptoms from the time of their diagnosis. Meanwhile, patients with aggressive lymphomas undergo unpredictable illness courses, resulting in goals of care conversations occurring late in the illness trajectory and aggressive care being received in the last 30 days of life. Early palliative care alongside usual cancer care has been shown to improve patient outcomes such as symptom burden, mood, and quality of life in patients with solid tumours (e.g. lung, breast or gynecological cancers), but has not been explored among patients with blood cancers to date. The goal of this clinical trial is to a brief early palliative care intervention for patients with multiple myeloma and aggressive B cell lymphoma attending the Princess Margaret Cancer Centre. The main goals of the study are: * To see if it is possible to apply the early palliative care intervention for patients with multiple myeloma and aggressive lymphoma * To see if this early palliative care intervention works well for these patients * To compare patient experiences with early palliative care and usual care. Participants will be randomly assigned to one of two groups: one group will receive early palliative care in addition to usual care from their blood cancer doctor, and the other group will receive usual care from their blood cancer doctor only. All participants will be asked to fill out questionnaires about their symptom burden, mood, quality of life, and satisfaction with care throughout the study. Some participants will also be asked to take part in interviews at the end of the trial to answer questions about their experience taking part in the study. Researchers will compare the results between the two groups to see if there are any improvements in quality of life for the patients who received early palliative care. The researchers will use the results of this study to guide in the development of a larger clinical trial. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

08/27/2024

Locations: Princess Margaret Cancer Centre, Toronto, Not set

Conditions: Multiple Myeloma in Relapse, Multiple Myeloma, Refractory, Multiple Myeloma Stage III, Multiple Myeloma Progression, Multiple Myeloma, B Cell Lymphoma, Lymphoma, B-Cell, Aggressive Lymphoma

Register for Updates

Learn More ›

Myeloproliferative Neoplasms (MPNs) Patient Registry

NCT02760238

Recruiting

The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease.

Gender:

ALL

Ages:

All

Trial Updated:

08/26/2024

Locations: Princess Margaret Cancer Centre, Toronto, Ontario

Conditions: Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Mastocytosis, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myelomonocytic, Juvenile, Chronic Eosinophilic Leukemia-not Otherwise Specified, Myelodysplastic-Myeloproliferative Diseases, Neoplasms, Leukemia, Myelomonocytic, Chronic

Register for Updates

Learn More ›

All Clinical Trials in Canada

Match to Clinical Trials